IN2014DN02060A - - Google Patents

Info

Publication number
IN2014DN02060A
IN2014DN02060A IN2060DEN2014A IN2014DN02060A IN 2014DN02060 A IN2014DN02060 A IN 2014DN02060A IN 2060DEN2014 A IN2060DEN2014 A IN 2060DEN2014A IN 2014DN02060 A IN2014DN02060 A IN 2014DN02060A
Authority
IN
India
Prior art keywords
patient
benzimidazol
methylpiperazin
quinolin
tautomer
Prior art date
Application number
Other languages
English (en)
Inventor
Suraj Prakash Anand
Catherine Wynnette Reddick
Michael Shi
Mary Ellen Steed
Eugene Youchin Tan
Yongyu Wang
Mario Reinhard Stegert
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2014DN02060A publication Critical patent/IN2014DN02060A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN2060DEN2014 2011-09-15 2012-09-07 IN2014DN02060A (OSRAM)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161535142P 2011-09-15 2011-09-15
PCT/US2012/054046 WO2013039764A1 (en) 2011-09-15 2012-09-07 Use of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one in the treatment of cancer in moderate hepatic impaired patients

Publications (1)

Publication Number Publication Date
IN2014DN02060A true IN2014DN02060A (OSRAM) 2015-05-15

Family

ID=46846036

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2060DEN2014 IN2014DN02060A (OSRAM) 2011-09-15 2012-09-07

Country Status (12)

Country Link
US (1) US20140221389A1 (OSRAM)
EP (1) EP2755655A1 (OSRAM)
JP (1) JP2014526506A (OSRAM)
KR (1) KR20140062485A (OSRAM)
CN (1) CN103826634A (OSRAM)
AU (1) AU2012308993A1 (OSRAM)
BR (1) BR112014005653A2 (OSRAM)
CA (1) CA2848210A1 (OSRAM)
IN (1) IN2014DN02060A (OSRAM)
MX (1) MX2014003182A (OSRAM)
RU (1) RU2014114827A (OSRAM)
WO (1) WO2013039764A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
EP3093014A1 (en) * 2015-05-13 2016-11-16 Aventis Pharma S.A. Cabazitaxel and its use for treating cancer
US20220331274A1 (en) * 2019-09-11 2022-10-20 Inspirna, Inc. Methods of treating cancer
EP4073025B1 (en) 2019-12-13 2024-03-27 Inspirna, Inc. Metal salts and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60132937T2 (de) 2000-09-11 2009-02-12 Novartis Vaccines and Diagnostics, Inc., Emeryville Verfahren zur Herstellung von Benzimidazol-2-yl -Chinolinonderivaten
AU2003288899B2 (en) 2002-08-23 2009-09-03 Novartis Vaccines And Diagnostics, Inc. Benzimidazole quinolinones and uses thereof
AU2003290699B2 (en) * 2002-11-13 2009-08-27 Novartis Vaccines And Diagnostics, Inc. Methods of treating cancer and related methods
CN100377709C (zh) * 2002-11-13 2008-04-02 希龙公司 受体酪氨酸激酶抑制剂的制药用途及相关检测方法
DE602004022540D1 (de) * 2003-05-27 2009-09-24 Robert P Haegerkvist Verwendung von tyrosin-kinase-hemmern zur behandlung von diabetes
KR101368519B1 (ko) * 2005-05-23 2014-02-27 노파르티스 아게 결정형 및 기타 형태의 4-아미노-5-플루오로-3-[6-(4-메틸피페라진-1-일)-1h-벤즈이미다졸-2-일]-1h-퀴놀린-2-온 락트산염
PE20091628A1 (es) 2008-03-19 2009-11-19 Novartis Ag Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona
US20110237540A1 (en) * 2009-11-23 2011-09-29 Crawford Thomas C Cyclodextrin-based polymers for therapeutic delivery

Also Published As

Publication number Publication date
JP2014526506A (ja) 2014-10-06
MX2014003182A (es) 2014-09-22
KR20140062485A (ko) 2014-05-23
WO2013039764A1 (en) 2013-03-21
CA2848210A1 (en) 2013-03-21
US20140221389A1 (en) 2014-08-07
AU2012308993A1 (en) 2014-03-27
CN103826634A (zh) 2014-05-28
BR112014005653A2 (pt) 2017-03-28
RU2014114827A (ru) 2015-10-20
EP2755655A1 (en) 2014-07-23

Similar Documents

Publication Publication Date Title
UA114726C2 (uk) 1,4-дизаміщені аналоги піридазину та способи лікування пов'язаних з дефіцитом smn станів
UA118759C2 (uk) Сполуки 3,4-дигідроізохінолін-2(1н)-ілу
MX2014005928A (es) Inhibidores ciclicos de glutaminasa.
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
PH12015501965B1 (en) Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
IN2014DN10670A (OSRAM)
IN2014MN00988A (OSRAM)
IN2014MN01640A (OSRAM)
MD20160017A2 (ro) Polimorf al inhibitorilor SYK
IN2015MN00002A (OSRAM)
NZ709153A (en) Pyrimidinone derivatives having human neutrophil elastase inhibitory activity
HK1212977A1 (zh) 苯達莫司汀衍生物及其使用方法
EA201391171A1 (ru) Формы рифаксимина и их применение
WO2014160281A3 (en) Method of enhancing delivery of therapeutic compounds to the eye
PH12015501586A1 (en) 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2) inhibitors
IN2015DN01151A (OSRAM)
MX2021015824A (es) Sales de inhibidor de pim cinasa.
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
SG10201900541QA (en) Derivatives of xanthone compounds
MX357763B (es) Tratamiento para cancer pancreatico.
NZ700356A (en) Pyrazole compounds as sglt1 inhibitors
IN2014DN02060A (OSRAM)
PH12014502065A1 (en) Vesicular formulations
IN2014DN03010A (OSRAM)
PH12014500577A1 (en) Sulfonic acid salts of heterocyclylamide-substituted imidazoles